Selzentry™ (maraviroc) HIV Treatment
A Panel Discussion among Five HIV Specialists
Prepared by Panel Intelligence, LLC
Price $2500
Deliverable: Transcript with key findings.
Study Description and Objectives:
To conduct a panel among HIV specialists to better understand changes in physicians’ treatment regimens and prescription patterns since Selzentry™ (maraviroc) was released on August 6, 2007.
§ Understand the market size and patient population that uses maraviroc
§ Identify physicians’ adoption of maraviroc and inclusion in treatment plans (patient and provider drivers)
§ Assess how maraviroc has changed treatment plans (prescription patterns, dosing, etc.)
§ Discuss physician and patient experiences with maraviroc
o Identify the side effects and their effect on prescribing
o Assess the benefits and risks of incorporating maraviroc in a treatment plan
§ Examine recent clinical data about maraviroc
§ Discuss barriers and facilitators to treating with maraviroc
§ Review coverage and reimbursement for maraviroc
§ Explore other possible uses of maraviroc and the impact of other products in the CCR5-coreceptor antagonist class currently in the pipeline
§ Examine future trends in the next 6 months to 1 year
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Pfizer |
PFE |
Selzentry™ |
|
Roche Laboratories Inc. |
RHHBY |
Fuzeon® |
|
Tibotec Therapeutics/Ortho Biotech |
|
INTELENCE™ |
|
Merck |
MRK |
ISENTRESS™ |
Inclusion Criteria:
|
Inclusion Criteria |
§ US Board-certified in specialty § 2 to 30 years of experience post-training § Must have treatment experience with maraviroc § From academic medical centers and community practices o Goal is for 50% from academic centers and 50% from community practices § Treat at least 50 HIV patients per month § Request disclosure of past and current consulting relationships |
To purchase this report or request additional information, contact:
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Infectious Disease |